September 20 – 22, 2017 | San Diego, CA
Sheraton San Diego Marina

Speakers

Expand/Collapse

David Thurston
Chief Scientific Officer
Femtogenix

David Thurston is CSO of Femtogenix Ltd and Professor of Drug Discovery in the Institute of Pharmaceutical Science at King’s College London. He has a first degree in Pharmacy, an MSc in Precision Medicine and a PhD in synthetic medicinal chemistry. His academic research team discovered the first example of a C8-linked DNA-interactive PBD dimer, and in 2000 he co-founded the oncology biotech company Spirogen Ltd to commercialize this technology, acting as its CSO until 2011. In 2015 he co-founded Femtogenix Ltd to develop the next generation of DNA-interactive sequence-selective ADC payloads based on work carried out in his King’s College laboratories since 2012. He is also a co-founder of Transcriptogen Ltd, which focusses on the discovery and development of small-molecule transcription factor inhibitors as oncology agents. David has published widely in the medicinal chemistry area, is author of the textbook Chemistry and Pharmacology of Anticancer Drugs, and is Editor-in-Chief of the Drug Discovery book series of the Royal Society of Chemistry.

Day Two

Friday 22 September, 2017

08.40 | Pyridinobenzodiazepines (PDDs): A Novel Class of ADC Payloads

Annie Yang Weaver
Clinical Scientist
CytomX

Annie Yang Weaver is a Clinical Scientist at CytomX Therapeutics, where she works on the development of drug conjugates using the ProbodyTM technology. Prior to joining CytomX, Annie completed a postdoctoral fellowship at Genentech. She received her doctorate and bachelor’s degrees from Harvard University.

Anthony Haight
Director, Development Sciences, Process R&D
AbbVie

Armin Storz
Area Sales Manager
Bausch+Stroebel Ilshofen

In 1987, Armin Storz started at Bausch+Stroebel Ilshofen as an employee in the technical field. After having finished his economist degree in 2000 he started in the international sales and project managing department where he was involved in many high tech projects for the pharmaceutical industry. With his excellent experience in primary packaging machines, Armin Storz has since then made significant contributions to technological developments and accompanied numerous projects from the first inquiry to the SAT  (site acceptance test). Since 2000, he has been in charge of the North American territory as a Area Sales Manager.

Bryan Fonslow, PhD
Market Development Scientist
SCIEX Separations

Charlie Johnson
Chief Executive Officer
ADC Biotechnology Ltd

Day One

Thursday 21 September, 2017

16.30 | Lock-Release: Delivering a solid phase solution to conjugators

David Rabuka
Global Head of Research and Development, Chemical Biology
Catalent

David Rabuka is Global Head of Research and Development, Chemical Biology at Catalent Biologics with overall R&D responsibility for the SMARTag® protein conjugate platform.  He joined Catalent Biologics following Catalent’s acquisition of Redwood Bioscience Inc., where he was previously founder, President and Chief Scientific Officer.  David received a Ph.D. in Chemistry at the University of California, Berkeley as a Chevron Fellow in the lab of Professor Carolyn Bertozzi where his research included developing and applying Redwood’s platform technology to cell surface modification.  Prior to pursuing his Ph.D., David worked at the Burnham Institute synthesizing complex glycans and later at Optimer Pharmaceuticals, which he joined as an early employee, focused on the development of glycan and macrolide based antibodies.  David graduated with double honors B.S. in Chemistry and Biochemistry from the University of Saskatchewan where he received the Dean’s Science Award and holds a M.S. in Chemistry from the University of Alberta.  He is an author of over 40 major publications as well as numerous books chapters and patents.

Dr. Jimmy Bao
Executive VP of Antibody Discovery and Therapeutics
Abmart

Jimmy Bao, Ph.D., Research Investigator, currently Executive VP of Antibody Discovery and Therapeutics at Abmart (Shanghai) Co., Ltd, has broad research interest in immune-oncology and immunobiology. Dr. Bao has over 18 years of drug development experience in novel therapeutics including antibodies, ADCs, recombinant proteins, and DNA vaccines etc for the treatment of cancer, ophthalmic diseases, rare diseases, complement-dysregulatory, and autoimmune diseases. Dr. Bao received training in medicine and pharmacology from Shanghai Medical University, obtained Ph.D. from Karolinska Institute and completed his postdoc in Columbia University Center for Neurobiology and Behavior in the laboratory of Dr. Kandel, year 2000 Nobel laureate in Physiology or Medicine. Since 1998, Dr. Bao has worked mostly in California in a number of biopharmaceutical companies including GSK (“GSK”), Catalyst Biosciences (“CBIO”), MacuSight, Inc., and Quassia Biopharma, Co., in positions with increasing responsibilities from drug discovery, research and development, to regulatory filing and clinical studies. Dr. Bao has been involved in research and development of a number of drug candidates including MPL, the adjuvant used in GSK’s HPV vaccine Cervarix®.

Elaina Gartner
Medical Director
Seattle Genetics

Ian Moore, Ph.D
Global Technical Marketing Manager
SCIEX

Ian Schwartz

Ian Schwartz recently joined Sartorius Stedim Biotech as a Process Development Consultant. Ian has over 12 years of experience in the biotechnology industry and specializes in developing and implementing scalable platforms for process development and manufacture of biologics to speed development and reduce risks to successful manufacture. Prior to joining Sartorius Stedim Biotech, Ian gained experience in process development and manufacturing operations through positions of increasing responsibility at ImmunoGen, MedImmune, and Agensys.  

Josh Snyder
Associate Scientist
Agensys

Jutta Wanner
Vice President, Research
BlinkBio Inc.

Kathy Kozak
Senior Scientist
Genentech

Kevin Anderson
Associate Director,Analytical Biochemistry
Seattle Genetics

Michael Molony
Director, Analytical Development & QC
Ajinomoto Althea

Philipp Müller
Principal Scientist, Cancer Immunology & Immune Modulation
Boehringer Ingelheim

Dr. Philipp Müller received his PhD in Biochemistry from the University of Basel in 2009 (Biozentrum, Prof. Jean Pieters), with a major focus on the immunology of infectious diseases, immune cell signaling and in vivo models of immune cell function as well as development. During the last 8 years his research has been dedicated to cancer immunology and immunotherapy. He has worked on and published in high ranking journals on the immune-promoting properties of Antibody-Drug-Conjugates, bispecific antibody formats as well as agonistic antibodies, such as anti-CD40, and their therapeutic combination with immune-checkpoint blockade. Dr. Philipp Müller is currently working as Principal Scientist within the Cancer Immunology & Immune Modulation Department of Boehringer Ingelheim (Biberach an der Riß, Germany) with a major focus on cancer vaccines and oncolytic viruses. .

Priyaranjan Pattanaik
Associate Research Director – ADCs
Syngene International Ltd.

Priyaranjan is a structural biologist by training. After completing PhD at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), Bangalore, Priyaranjan conducted post-doctoral research at Case Western reserve University. He joined Syngene in 2008. For the last several years, he has led ADC discovery research at Syngene and established successful collaborations with multiple global pharma companies.

Rand Jenkins
Scientific Director
PPD Laboratories

Rand Jenkins is Scientific Director for PPD Laboratories Bioanalytical Labs in Richmond, VA, and Middleton, WI, USA. He received a B.S. in Chemistry in 1972 from the University of Nevada and attended graduate school at the University of Washington, while conducting GC-MS-based bioanalysis research as a Senior Research Technologist in the Pathobiology and Psychiatry Departments. He was an Applications Chemist at Finnigan Instruments (now part of Thermo Fisher Scientific) and a Research Chemist at the National Marine Fisheries Service/NOAA, conducting environmental bioanalysis in marine organisms. Throughout the 1980’s, Mr. Jenkins was Director of R & D at J&W Scientific (now part of Agilent), where he developed the first commercial bonded-phase fused silica capillary columns for gas chromatography. Mr. Jenkins returned to pharmaceutical bioanalysis in 1994, joining Pharmaco, which later merged with PPD. Mr. Jenkins currently provides scientific leadership to the LC-MS R&D teams and support to cross-functional initiatives involving multiple laboratory groups in evaluating and implementing new technologies and expanding application areas. Mr. Jenkins is also an active participant in several cross-industry collaborations, including the Protein LC-MS Bioanalysis Committee of the AAPS Bioanalytical Focus Group, the AAPS ADC Discussion Group, and the Global Biomarker Standardization Consortium of the Alzheimer’s Association.

Robert Lyon
Director, Chemistry
Seattle Genetics

Day Two

Friday 22 September, 2017

08.10 | Design Principles for Maximizing the Drug Delivery Efficiency & Therapeutic Index of ADCs

Shyra Gardai
Associate Director
Seattle Genetics

Alison Betts
Modelling & Simulation Leader & Associate Research Fellow
Pfizer

Alison Betts works at Pfizer in the Pharmacokinetics, Dynamics and Metabolism (PDM) department in Groton CT, where she is discipline lead for the Translational Modeling and Simulation group. The focus of this group is to develop mechanistic models in order to aid decision making, validate targets, select optimal compounds and provide clinical translation for preclinical programs across a diverse range of therapeutic areas. Alison is also modeling and simulation (M&S) lead for the Oncology Research Unit (east). In this role she leads a team responsible for using M&S strategies in support of novel antibody drug conjugates as a selective mechanism for the treatment of cancer. In addition to her role in oncology, Alison is preclinical PK/PD lead supporting the Pfizer Center of Therapeutic Innovation (CTI) in New York and Boston, where she applies M&S approaches to help the CTI programs achieve their portfolio goals. Prior to these roles, Alison has worked across many Research Units at Pfizer (Pain, GU, CVMED and Antibacterial) to establish the use of M&S and translational pharmacology to drive projects forward. Alison began her career at Pfizer in Sandwich, UK in 1994. She spent 10 years working in PDM as a discovery team leader before transferring to the preclinical PK/PD group to focus on her passion for mathematical models and their application in research.  

Allan Davidson
Analytical Development Manager
Piramal

Amy Han
Director of Chemistry
Regeneron Pharmaceuticals

Amy Han is a Director of Chemistry at Regeneron Pharmaceuticals. Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. Amy recently published a chapter on next generation ADC technologies in ‘Antibody-Drug Conjugates: Fundamentals, Drug Development, Clinical Outcomes to Target Cancer’.

Andreas Pahl
Chief Scientific Officer
Heidelberg Pharma

Professor Pahl has 20 years’ experience in research and teaching and excellent expertise in biochemistry, pharmacology and toxicology. In 2008 he joined industry to pursue drug development for inflammatory and autoimmune diseases at Nycomed and Takeda.  In 2012 he joined Heidelberg Pharma as the CSO extending his expertise to the area of oncology and antibody-drug conjugates. Since 2016 he is also CSO of Wilex, the mother firm of Heidelberg Pharma. Professor Pahl continues to be adjunct Professor for pharmacology and toxicology at the University of Erlangen-Nuremberg

Day One

Thursday 21 September, 2017

17.30 | Antibody Targeted Amanitin Conjugates (ATACs): Expanding the ADC Landscape With a New Payload Targeting RNA Polymerase II

Andrew Huang
Chief Scientific Officer
Mabplex

Andrew C Huang has developed a robust and proprietary technology platform for the manufacturing antibody drug conjugates (ADC) utilizing the Covalent Thiol Conjugation Technology. The resulting Hertuzumab Vedotin of China 1st ADC has entered the Phase-I and II Clinical Trials. Currently, we are focused on the development of the next generations of technology and platforms and on molecular designs of monoclonal antibody, linker chemistry and cytotoxic payloads for developing new generation of ADC. Andrew Huang was SVP for ADC research and development since 2013. Prior to joining MabPlex, Huang served as a biomedical researcher at UCLA for 17 years, engaging on molecular medicine, including brain aging, diabetes, stem cells and protein folding research. He published near 100 research articles, journal reviews, book chapters and patents etc. His past public presentations include the topics of molecular mechanism of type II diabetes, brain aging and longevity. Before that, he held a senior scientist position at Amcyte Diabetes Inc, a company focused on stem cell research at Santa Monica, California. After returned to China, he served VP of RC Biotechnologies LTD. During his doctorate research, he developed a RIA platform of antibody conjugation with fluorescent moiety and radioisotope. Huang holds a PH.D. in Biochemistry from the Iowa State University and a Bachelor of Science degree in Cell Biology from Xiamen University. Postdoctoral at UCLA for the brain aging research.  

Angela Romanelli
Executive Director, Translational Medicine
ImmunoGen

Angela Romanelli is currently Executive Director of Translational Medicine at ImmunoGen. For the past 20 years, she has been involved in oncology drug development, studying tumor biology and oncogenic molecular pathways toward the identification of biomarkers. Dr. Romanelli joined ImmnunoGen in 2013. Her team of scientists focuses on enabling the selection of patients who will benefit most from treatment with ImmunoGen’s new generation of antibody conjugates. Her team also leads companion diagnostics strategies for all development programs. Prior to 2013, she was head of the Clinical Biomarker Integration group at Sanofi. Angela obtained her doctorate in biochemistry from the Université de Montréal and pursued her post-doctoral work at Harvard Medical School.

Anna Berkenblit
Chief Medical Officer
ImmunoGen

Anna Berkenblit joined ImmunoGen as the Chief Medical Officer in April 2015. Prior to joining ImmunoGen Anna was the Senior Vice President and Head of Clinical Development at H3 Biomedicine. Anna has also held positions of responsibility at AVEO and Pfizer. Anna received her Doctor of Medicine from Harvard Medical School.

Anu Conor
Safety Assessment Expert, Preclinical Safety Group
Novartis

Anu Connor is a board certified toxicologist, graduating from Northeastern University with a PhD in Biomedical Sciences with a specialization in Toxicology.  After graduation, she joined Sepracor in Marlborough MA as a toxicologist developing CNS small molecules. She then moved to the west coast and spent several years in the Bay Area at Genentech as a scientist and pharmacology subteam leader in the biotherapeutics group. She has been working on ADC development since 2008 at broad range of companies, spanning from start up to large pharma. She currently works at Novartis as a Safety Assessment Expert in the Preclinical Safety Group and is responsible for the oversight and strategic development of the Antibody Conjugate portfolio.

Ben Shen
Principal Scientist, Preclinical & Translational Pharmacokinetics & Pharmacodynamics
Genentech

Ben Shen has over 20 years experience in research and drug development with 16+ years at Genentech. Ben focuses on large molecule drug development such as antibody and antibody drug conjugate by determining the metabolic fate, biodistribution, clearance mechanism, and elimination pathways. He has supported the development of a variety of projects from Early/Late Stage Research, Early Development to Post-marketing, and contributed to numerous regulatory filings (IND & BLA). Received MD and MS from China and conducted postdoctoral training at UCSF followed by working as a research biologist at UCSF and Children’s Hospital Oakland Research Institute; joined the PKPD Dept. of Genentech in 1996.  Ben has published over 30 peer-reviewed papers with many of them as 1st or last author such as J.B.C., Nature Biotech, and presented nearly 80 abstracts/posters at scientific conferences. Ben is a member of AACR, AAPS, and ASCPT, APS, and served as an Editorial Board Member for the Journal of molecular and cellular proteomics.

Day Two

Friday 22 September, 2017

16.30 | Preclinical ADME Characterization of THIOMABTM-Antibiotics Conjugates (TAC) to Support Clinical Development of TAC for treating StaphA Infectious Disease

Brian Hosken
Principal Scientist
AbbVie-Stemcentrx

Brian Hosken is an analytical development chemist with extensive experience characterizing ADCs, mAbs, linker-drugs and their related impurities. Brian leads analytical development activities at Abbvie-Stemcentrx where he developed the control system strategy for the lead candidate, Rova-T, which is currently in pivotal PhII studies. Brian previously worked in the Protein Analytical Chemistry Department at Genentech where he was the analytical lead on several mAb and ADC molecules.  Brian has a Ph.D. in Chemistry from Texas A&M University and a B.S. in Chemistry from Spring Hill College.  He can be reached by email at brian.hosken@abbvie.com.

Brian Schmidt
Associate Director
Bristol-Myers Squibb

Brian is an Associate Director is of Quantitative Systems Pharmacology at Bristol-Myers Squibb. Brian focusses on developing and applying computational approaches to integrate datasets, better understand biological systems, and develop predictions of efficacy for new therapeutic compounds. Brian has seven years of post-PhD experience in computational and systems modeling roles, including four years in pharmaceutical industry QSP.

Bruce Nianhe Han
Chief Scientific Officer
NewBio Therapeutics

Dr. Han is currently Chief Scientific Officer at NewBio Therapeutics.  He received a B.S. degree in nuclear chemistry from Peking University,and a Ph.D. degree in organic chemistry from Columbia University.  He conducted postdoctoral research in antibody engineering with Dr. Richard Lerner (1990-1994), and in medicinal chemistry with Dr. Dale Boger (1994-1996) both at The Scripps Research Institute. He joined Amgen in 1996 and conducted small molecule drug discovery for 12 year there.  After coming back to China in 2008 and leading integrated drug discovery teams for 5 years in Shangpharma , he joined NewBio Therapeutics (NBT) as CSO in 2013, leading the development of NBT’s site-specific conjugation technology and antibody-drug conjugates (ADC) as anti-cancer therapeutics. In his career so far, he has worked on many therapeutic areas, including oncology, metabolic disease, inflammation, anti-viral and central nervous system, and has led teams to deliver five small molecule and one ADC clinical candidates.  Dr. Han has published more than sixty of peer-reviewed publications and PCT patent applications.  

Christoph Rader
Associate Professor
The Scripps Research Institute

Dr. Christoph Rader has been an Associate Professor with tenure at The Scripps Research Institute in Jupiter, Florida (TSRI-FL) since 2012 and currently also serves as Acting Associate Dean of Graduate Studies. Dr. Rader joined TSRI-FL after 9 years as the Head of an Antibody Technology Section at the National Cancer Institute, National Institutes of Health (NIH) in Bethesda, Maryland.  Prior to this position, Dr. Rader was Assistant Professor at The Scripps Research Institute in La Jolla, California (TSRI-CA) from 1999 to 2003.  He was a postdoc in the laboratory of Dr. Carlos F. Barbas III at TSRI-CA from 1996 to 1999 after graduating with a Ph.D. in biochemistry and molecular biology from the University of Zurich in Zurich, Switzerland.  Dr. Rader is a leading scientist in antibody drug and target discovery for cancer therapy.  He has authored >100 journal articles and book chapters, is named inventor on >25 issued and pending patent applications, and lectures frequently.  Antibodies developed in Dr. Rader’s NIH-funded laboratories at TSRI-CA, NIH, and TSRI-FL have been licensed to companies and translated to clinical trials.  A particular focus of Dr. Rader’s TSRI-FL laboratory is devoted to antibody technologies at the interface of biology and chemistry, including the generation of site-specific antibody-drug conjugates and chemically programmed antibodies.  In addition to his academic activities, Dr. Rader serves on the Scientific Advisory Boards of NBE-Therapeutics, Inc. (Basel, Switzerland) and BlinkBio, Inc. (Jupiter, FL).

Daniela Tomazela
Associate Principal Scientist
Merck

Daniela Tomazela is an Associate Principal Scientist from Merck. Prior to joining Merck in February 2011 Daniella was a Senior Fellow in Genome Sciences  at the University of Washington. Daniella has also held the position of Mass Spec Manager at Waters Corporation. She received her PhD in Organic Chemistry – Mass Spec from Universidade Estadual de Campinas

Day Two

Friday 22 September, 2017

16.00 | Developing the Magic Bullet Outside Oncology: An Analytical Perspective

David Bramhill
Consultant
Bramhill Biological Consulting

Dr. Bramhill has over 20 years experience in biologics, both in large biopharma and startup biotech companies. He has experience in isolating and improving antibodies using phage display and is an inventor on library design techniques for small scaffolds. He also has experience in diverse expression systems for producing antibodies, antibody fragments and different scaffolds. He has taught numerous technical courses for over 10 years at international conferences.

David Tice
Director, Research & Development
MedImmune

Dr. David Tice has over 17 years of biopharmaceutical research experience. He spent the last 14 years at MedImmune, a subsidiary of Astrazeneca, where he currently heads the Antibody Drug Conjugate research group. Throughout his tenure at MedImmune, David has led several preclinical/clinical phase programs employing various therapeutic approaches including monoclonal antibodies, immunoconjugates, peptide mimetics, and RNAi targeting various molecules important in the development of cancer.  Prior to this experience David worked at Genentech, Inc. where he focused on genomics-based target discovery and monoclonal antibody targeting in cancer.  David began his training at the University of Virginia where he received his PhD.

Day One

Thursday 21 September, 2017

18.00 | The Resistible ADC – Let Us Count the Ways

Don Bergstrom
Chief Medical Officer
Mersana Therapeutics

Dr. Bergstrom joined Mersana in January 2014, bringing a decade of industry experience in translational medicine and drug development. Prior to Mersana, Dr. Bergstrom spent four years as Associate Vice President and Global Head of Translational and Experimental Medicine at Sanofi Oncology, where he built a global team of laboratory and clinical scientists focused on defining and executing scientifically rigorous early development strategies. Dr. Bergstrom represented Sanofi in the governance of a number of collaborations with academic and industry partners. Prior to Sanofi, Dr. Bergstrom spent six years at Merck Research Labs in roles of increasing responsibility in the Clinical Molecular Profiling, Oncology Clinical Research and Experimental Medicine Oncology groups. Dr. Bergstrom completed his M.D. and residency at the University of Washington and his Ph.D. and post-doctoral training at the Fred Hutchinson Cancer Research Center.

Dongwei Li
Pharmacologist
Genentech

Dongwei Li is currently a PK Scientist in the Preclinical and Translational PKPD Department at Genentech. She has been working in the field of ADCs for the past 16 years and has made significant scientific contributions to the company portfolio. In addition, she applied her extensive ADC PK/PD knowledge in the understanding of the MoT and MoA of various platforms of ADCs.  Dongwei received her medical degree and training in otolaryngology (ENT) from Shanghai Medical College of Fudan University, where she had first-hand experience in managing patients both medically and surgically. After moving to US, Dongwei joined the neuroscience program at UW-Madison with a research focus on neuroimmunology. Dongwei also passed United States Medical License Exams; hence, she is certified by Educational Commission for Foreign Medical Graduate (ECFMG).

Ed Ha
Business Development
Solstice Bio

Ed Ha has been involved in Antibody Drug Conjugates for >15 years. Ed’s experience began in the early days of the in-house ADC group and luckily followed the T-DM-1 project from Early Discovery to Process Development/CMC collaborating with Immunogen and Seattle Genetics. Ed has worked with almost all of the payload classes used in ADC’s (Auristatins, PBD’s, Tubulysins, CC-1065’s, Nemorubicins, dPEG’s, etc..) After almost a decade at GNE, Ed joined Igenica to launch full ADC capabilities, with David Jackson, and developed an ADC platform with site-specific and homogenous conjugation tools. Ed is now at Solstice Biologics synthesizing and conjugating oligonucleotide payload-linkers to proteins to explore the frontier of a universal hydrophilic payload.

Eoin Cosgrave
Senior Scientist
Seattle Genetics

Eoin Cosgrave is a Senior Scientist in the Analytical Sciences group at Seattle Genetics. Eoin performs analytical characterization and comparability studies. Eoin is involved with Technology Development (evaluate new technology to improve capabilities for ADC analysis) and Method Development (generate new methods to support analysis of novel ADC chemotypes), as well as, Method Qualification (ensure program-specific capability of analytical methods)

Firelli Alonso
Senior Director, External Supply
Pfizer

Dr. Firelli Alonso is a Senior Director at Pfizer, Inc.  She heads the BioTherapeutics and Vaccines Outsourcing group in Worldwide Research and Development.  Fi has more than 33 years of combined experience in research, development, and cGMP production of biological products and vaccines, and more than 10 years of experience in outsourcing, project / contract management, and technology transfer to qualified third parties.  Her areas of expertise include viral vectors and vaccine development, biotherapeutics and vaccine process development and cGMP production, project management, technology transfer, outsourcing, and budgets and operations. She obtained her Ph.D. in Microbiology from the University of Alabama in Birmingham, followed by postdoctoral research at the U.S. Army Medical Research Institute for Infectious Diseases, Sloan-Kettering Institute for Cancer Research, and Rutgers University Center for Advanced Biotechnology and Medicine.  Prior to working for Wyeth / Pfizer in 1996, Fi was at The Salk Institute (Government Services Division), a vaccine contract manufacturer for the U.S. Army.

Francois D’Hooge
Head, Bioconjugation
Novasep

PhD in Rouen, France ( 2000-2004) on the synthesis of fluorinated glycopeptide to stabilise the protein-sugar bond. Then, a few  post docs including two years (2004-2006) at the University of Tokyo, doing total synthesis of a complex alkaloid, and two years at the University of Oxford ( 2008-2010), on a Bill and Melinda Gates fellowship for new radioactive imaging techniques for Mycobacterium Tuberculosis, where I started working on bioconjugation ( radioactive sugars on proteins) Joined Spirogen (London, UK) in 2011 to start its in house conjugation group, from 0 staff to 5 and turning over 1000 ADCs in 5 years. Joined Novasep in May 2016 to head its new bioconjugation facility in Le Mans

Francois Fauteux
Research Officer
National Research Council Canada

François Fauteux is Research Officer with National Research Council Canada, Information and Communication Technologies since 2009. He is currently Principal Investigator in the Biologics and Biomanufacturing Program (Target Selection and Prioritization).

Hui Li
Chief Executive Officer
Levena Biopharma

Dr. Hui Li is currently VP of business development and general manager of China Operation at Sorrento Therapeutics. In his role, he is responsible for Sorrento's partnership set up and licensing negotiations, as well as operation of Sorrento’s Chinese subsidiaries. Prior to joining Sorrento, he was CEO at Levena BioPharma, a biotech company focused on antibody-drug conjugate (ADC) discovery and production. From 2010 to 2015, Dr Li served as Executive Director of business development at PPD and Head of Business Development at its discovery unit, BioDuro. Before PPD/BioDuro, Dr. Li spent 10 years at Pfizer Global Research & Development, La Jolla Laboratories and has led research programs in a number of disease areas including oncology, metabolic diseases, anti-viral, and ophthalmology. He is a co-inventor of Filibuvir (PF-00868554), a Hepatitis C Virus polymerase inhibitor advanced into phase II clinical trials and MS-553, an oral therapy for diabetic retinopathy, which has been out-licensed to Ming Sight for clinical development in both US and China. Dr. Li obtained his B.S degree from Peking University and Ph.D in chemistry from University of California, San Diego.

Day Two

Friday 22 September, 2017

09.40 | Preclinical Development of Superior ADCs Incorporating Novel Linker & Warhead Designs

Giorgio Salciarini
Technical Business Development Manager
BSP Pharmaceuticals

Giorgio is part of the Business Unit,  with responsibility of coordinating Business Development activities He joined BSP Pharmaceuticals in 2008 as Manufacturing Manager than moved to BD in 2014. Prior to joining BSP Pharmaceuticals, Giorgio has achieved a significant experience in Manufacturing and Operation at Bristol Mayers-Suibb where developed his professional and technical growth. Giorgio holds a degree in Pharmaceutical Chemistry and Technologies from the University of Perugia.  

Glenn Petrie
Senior Scientific Advisor

Dr. Glenn Petrie is a Senior Scientific Advisor at EAG Laboratories. He has over 20 years experience in the drug development arena with a focus on biopharmaceuticals.  As a director at a major CRO he has served as team leader in the development, Chemistry Manufacture and Control (CMC) design and IND submissions for a wide variety of biopharmaceuticals (monoclonal antibodies, drug conjugates, peptides, etc.). Dr. Petrie is a subject matter expert in the analysis of proteins including HPLC, mass spectroscopy, ELISAs and electrophoresis. He received his B.A. in Biochemistry at Rice University and his doctorate in Biochemistry at the University of Illinois Urbana-Champaign.

Greg Thurber
Assistant Professor
University of Michigan

Greg Thurber is the Assistant Professor of Chemical and Biomedical Engineering at the University of Michigan. Prior to joining the University of Michigan in 2014 Greg was an Instructure at the Center for Systems Biology and Research Fellow at Harvard Medical School. Greg received his PhD in Chemical Engineering at Massachusetts Institute of Technology.

Hans-Georg Lerchen
Principal Scientist, Medicinal Chemistry
Bayer

Hans-Georg Lerchen is a Principal Scientist in the Medicinal Chemistry unit of Bayer AG, Pharmaceuticals Division. With a 28 years background in MedChem he is author or co-author of 73 patents or patent applications and 16 publications. His current research focus is drug delivery systems, prodrugs and in particular antibody drug conjugates.  

Heather Donaghy
Research Analyst, Beacon
Hanson Wade

Beacon ADC’s head analyst has been at Hanson Wade for almost 2 years now. Her role is to ensure that all relevant data on clinical stage ADCs is kept up to date on Beacon ADC, and as such is in a unique position to provide an impartial overview of the current pipeline. Heather has a immunology background, having completed her PhD at Imperial College, London and post doc in Sydney.

Jack Sadowsky
Scientist, Protein Chemistry
Genentech

Jack earned his Bachelor’s degree in Chemistry from Pomona College and his Ph.D. in Chemistry from the University of Wisconsin – Madison.  His graduate work focused on the development of non-natural, oligomeric (beta-peptide) inhibitors of protein-protein interactions, leading to the identification of the first molecules in this class to potently antagonize members of the Bcl-2 protein family.  Following graduate studies, Jack joined the department of Pharmaceutical Chemistry at UCSF as a postdoctoral fellow where he worked on methods for probing and structurally characterizing allosteric sites on protein kinases with small molecules and peptides.  Jack then joined the startup company Carmot Therapeutics as a Scientist where he helped lay the foundation for a novel, high-throughput small molecule lead discovery technology called Chemotype Evolution.  In 2013, Jack joined Genentech as a Scientist where he works in the Protein Chemistry department leading the antibody-drug conjugation lab.  His current research interests are focused on chemical aspects of the development of next-generation ADCs and other bioconjugates, including new stable connection chemistries, cleavable linkers, and conjugation strategies.

James Christie
Scientist, Antibody Discovery & Protein Engineering Department
MedImmune

James Christie received his Ph.D. in chemistry from Colorado State University in 2006, where he studied polymer-based drug delivery systems under the supervision of Prof. David Grainger. He then continued research in the field of nanomedicine as a Japan Society for the Promotion of Science postdoctoral fellow in the laboratory of Prof. Kazunori Kataoka at the University of Tokyo, where he developed targeted nanoparticles for siRNA delivery. Dr. Christie is currently a scientist at MedImmune working to improve conjugation technologies for production of antibody-drug conjugates (ADCs) as well as targeted nanoparticles. Dr. Christie has co-authored over 30 publications and 3 patent applications.

Jan Pinkas
Executive Director, Pharmacology & Toxicology
ImmunoGen

Jan Pinkas is the Executive Director of Pharmacology & Toxicology at ImmunoGen. Jan leads a research team charged with utilizing animal model systems to understand features of ImmunoGen’s antibody-maytansinoid conjugates that impact tolerability, pharmacokinetics, metabolism and anti-tumor activity. In addition, Jan is responsible for preclinical development-related pharmacology, toxicology, and pharmacokinetic activities to support molecules advancing to IND as well as molecules currently in pivotal clinical development.

Jay Harper
Senior Scientist
MedImmune

Dr. Jay Harper received his Ph.D. in Cell & Developmental Biology from Harvard University in 2000 and conducted postdoctoral research on the initiation of the angiogenic switch with Marsha Moses, Ph.D. in the Vascular Biology Department at Boston Children’s Hospital.  After joining Genzyme in 2006, he worked on advancing the anti-TGFb antibody, GC1008, through the pipeline and into clinical trials for cancer.  Additionally, he helped build their antibody-drug conjugate (ADC) capabilities through both core capability development as well as by leading specific ADC project teams. He joined MedImmune in 2011 and since then has used his experience to progress MedImmune's ADC platform and advance preclinical research programs towards the clinic.  He has been the project lead for a number of different ADC projects and his team is helping to evaluate novel ADC technology to incorporate into MedImmune’s next gen ADCs.  In addition, he is currently working with the immunooncology group to determine if synergistic anti-tumor activity can be achieved by combining ADCs and IMTs and to determine the mechanism(s) of action of such enhanced activity. He is the co-inventor on a number of patents, has been invited to speak at various conferences and is either a lead author or a co-author on several journal articles, reviews and book chapters.

Jeff Milligan
Contractor
GEA

Jeff  specializes in supporting the manufacturing of parenteral products using the latest technologies and processes while ensuring regulatory compliance with the FDA, EU, PMDA, etc. Jeff’’s experience includes over 25 years in the injectable drug manufacturing business including technical, managerial and executive roles. I have had success in the management of facility expansion projects and business growth initiatives at 4 separate pharmaceutical companies.

Jian Wang
Senior Principal Scientist, Bioanalytical Sciences
Bristol-Myers Squibb

Dr. Wang is a Sr. Principal Scientist in the Bioanalytical Sciences Department at Bristol-Myers Squibb. Dr. Wang graduated from Beijing University (China) in 1987 and received his Ph.D. in analytical chemistry at Michigan State University in 1994.  Following postdoctoral training at the National Institutes of Health (NIH) in Maryland USA, he joined GSK in 1996 and then Bristol-Myers Squibb in 1997. Dr. Wang has 20 years of experience in Discovery and regulated bioanalysis in pharmaceutical industry. Dr. Wang has contributed in high throughput bioanalysis and bioanalytical chromatography. In recent years, Dr. Wang has been leading a group of scientists in developing ligand binding and LC-MS/MS hybrid assays for ADC bioanalysis in an LBA and LC-MS integrated approach. Currently, Dr. Wang serves as the coordinator of Regulated Bioanalysis Interest Group at ASMS and a sub-team lead of AAPS ADC bioanalysis committee.

John Lambert
Executive Vice President
ImmunoGen

Dr. Lambert earned a Ph.D. in Biochemistry (1976) from University of Cambridge (England, UK), under the supervision of Professor Richard N. Perham.  After postdoctoral training at the University of California, Davis (1976-1980), and University of Glasgow, Scotland (1980-1982), Dr Lambert joined the Dana-Farber Cancer Institute, Harvard Medical School working on the ImmunoGen-funded programs to develop antibody-drug conjugates (ADCs) and immunotoxins as anti-cancer therapeutics. The company established independent laboratories in Cambridge, Massachusetts in 1987. Dr. Lambert served as Chief Scientific Officer from 2008 until 2015, at which time he was appointed Distinguished Research Fellow. He served on the executive committee as Executive Vice President , Research, from 2008 until 2017, at which time he was appointed EVP Emeritus.  He is the author/co-author of over 120 peer-reviewed scientific publications. In 2016, Dr Lambert was elected a Fellow of the American Institute for Medical and Biological Engineering (AIMBE).

Day One

Thursday 21 September, 2017

08.10 | Keynote - Antibody Drug Conjugates: Current Status & Future Directions

07.30 | Honorary Chair

Day Two

Friday 22 September, 2017

07.30 | Honorary Chair

Jon Crate
Chief Technical Officer
FAI Testing Services

Jon Crate is the Chief Technical Officer at FAI Testing Services which he helped found.  He has over 25 years of experience in independent CTO and CRO services, overseeing projects in every phase of medical device and pharmaceutical production from basic and applied research, in-depth characterization of proteins including enzymes and monoclonal antibodies, characterization of glycosylation, comparison of biosimilars, method validation, validation of cleanliness protocols, stability, compatibility, and the testing and evaluation of packaging systems.  A significant portion of FAI’s work involves failure analysis, and independently conducted investigations of root cause. Jon holds a Bachelor of Science degree in Chemistry from the University of Central Florida, a Master of Science in Polymers and Materials Science and Engineering from the Georgia Institute of Technology, and three years of graduate level work in Molecular Cell Biology at the University of Alabama in Birmingham.

Jon Weidanz
Associate Vice President for Research & Professor of Biology
The University of Texas at Arlington

 

Dr. Weidanz is currently Associate Vice President for Research and Professor of Biology at UT Arlington. Dr. Weidanz Co-founded Abexxa Biologics in 2015 to develop breakthrough immunotherapeutics to revolutionize cancer treatments by providing highly effective antibody targeted therapies.  Dr. Weidanz previously was a University Distinguished Professor at The Texas Tech University Health Sciences Center (TTUHSC) and Chairman of the Department of Immunotherapeutics and Biotechnology, which he founded in 2012. 

 

Dr. Weidanz has over 25 years-experience in the field of cancer immunotherapy, with particular knowledge in the area of HLA-peptide biology and development of TCR-like antibody therapeutics.

Joseph Tweed
Scientist, Bioanalytical
Pfizer

Joseph Tweed is a bioanalytical scientist working at Pfizer Inc. located in Groton, CT.  Joseph has over 18 years of multi-disciplinary experience in the areas of drug discovery, drug development and pharmacology research.  He is responsible for developing and directing bioanalytical techniques via high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) and high resolution mass spectrometry (HRMS) aimed at improving the quality and the efficiency of day-to-day laboratory operations.  He is actively engaged in pursuing innovative bioanalytical approaches  for use in the regulated bioanalysis of small-molecules, nanoparticles, antibody-drug conjugates (ADCs) and biomarkers.  Joseph received his B.S. from Drexel University, a M.S. from Thomas Jefferson University and his M.B.A from the University of New Haven.

June Lu
Director, Translational Research
Endocyte

June Lu earned a B.S. degree in Analytical Chemistry from Zhejiang Institute of Technology and a Ph.D. degree in Chemistry (biochemistry division) from Purdue University. Her graduate research focused on folate receptor-targeted drug delivery and immunotherapy. Dr. Lu joined Endocyte in 2000 and has been actively working in the area of cancer immunotherapy, autoimmune/inflammatory diseases, drug resistance, immuno-oncology, and translational research. Her multi-disciplinary project leadership experiences in drug discovery have earned her about 23 peer-reviewed, mostly first-author scientific publications, 25 poster/oral presentations, 15 published patent applications, and 2 issued U.S. patents. Dr. Lu has been a member of the AACR since 2006 and currently holds the position of Director of Translational Research at Endocyte. The tentative title of her talk is “Combination Approaches with Immune Checkpoint Inhibitors and Immunomodulatory Agents to Enhance Folate Receptor-a/b Targeted Chemotherapy: Learning from Animal Models”.

Jyothi Swamy
Head of Global Marketing/ADC
MilliporeSigma

Jyothi has been in the pharmaceutical industry for over 25 years covering areas ranging from analytical method development, method validation, cleaning validation, stability, project management and marketing. Jyothi has been with MilliporeSigma for over 11 years in various roles, including Sr. Chemist, Quality Control Supervisor, Sr. Project Manager. Jyothi is currently the Head of Global Marketing focusing on ADCs.  Jyothi was an integral part of MilliporeSigma and Baxter collaboration working out the integration process with Baxter’s counterparts. She received her B.S. and M.S. at Bangalore University, India, M.S. at Indian Institute of Science, India, her Ph.D. in Synthetic Organic Chemistry at University of Missouri, St. Louis.   MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany

Day Two

Friday 22 September, 2017

07.00 | Breakfast Briefing: The Advantages of an Integrated Supply Chain

Kiyoshi Sugihara
Senior Researcher, Biologics & Immuno-Oncology Laboratories
Daiichi Sankyo

Kiyoshi Sugihara graduated in Veterinary Science from Hokkaido University and received his PhD in PK/PD study from the University. He joined Sankyo Co., Ltd. in 2001 and worked on research and development of small molecule compounds and antibodies in infectious disease area as a biologist at Daiichi Sankyo Co., Ltd and Daiichi Sankyo India Pharma Pvt., Ltd. He joined a research group for ADC programs in 2016 at Daiichi Sankyo Co, Ltd. and is currently a representative of pharmacology in DS-8201 project.

Kurt Gish
Associate Director II
AbbVie

Kurt Gish, Ph.D. leads the ADC Discovery Group at AbbVie’s site in Redwood City, California. Through multiple corporate spin-outs and acquisitions, this is his sixth company, but still his first job, and for the past 20 years has worked on antibody-drug conjugate (ADC) target selection and drug development at Affymetrix, Eos Biotechnology, PDL BioPharma, Facet Biotech, Abbott Labs, and now AbbVie. His research group specializes in the discovery, design, and pre-clinical development of ADCs, and works closely with his colleagues at all of AbbVie’s R&D sites to improve ADCs through protein engineering, linker chemistry, and novel mechanism-of-action payloads. He received his Ph.D. in Biological Sciences in 1994 from Stanford University in the laboratory of Charley Yanofsky, and did post-doctoral work at DNAX (now Merck Research Laboratories, Palo Alto). Kurt is an inventor on more than 20 issued U.S. patents, and an author on more than a dozen peer-reviewed publications, focused on cancer-specific antigens and their use for treating cancer.

Kyle Holen
Executive Medical Director
AbbVie

Kyle is responsible for a team of group medical directors, senior medical directors, medical directors, scientific directors and clinical scientists to create and execute drug development programs across a variety of heme/onc assets and indications. Kyle ensures appropriate clinical representation for regulatory, safety, and commercial interactions including driving key regulatory submissions. He also helps direct oncology priorities/initiatives at AbbVie and manages senior leadership communications.

Laurent Ducry
Leader & Head of Bioconjugates
Lonza

Laurent Ducry obtained his Ph.D. from the ETH Zürich (Switzerland) with Prof. F. Diederich in 1998. He then held a Swiss National Science Foundation postdoctoral fellowship at the University of Pennsylvania in Philadelphia with Prof. A. B. Smith, III and Prof. R. Hirschmann. He began his industrial carrier in process R&D at Lonza in Visp (Switzerland) in 2000. Since 2008, he is leading the antibody-drug conjugates R&D group of Lonza. He is the editor of “Antibody-Drug Conjugates: Methods and Protocols” (Springer, Humana Press, 2013).

Omar Hamdy
Senior Scientist I
AbbVie-Stemcentrx

I did my PhD at UC-Riverside working with Dr. Ryan Julian developing new MS techniques to apply in a bioanalytical setting (finished in 2015). I then joined the FDA for a short stint before joining Stemcentrx in early 2016 and have been there since then.

Lillian Skidmore
Associate Director, Translational Sciences
Ambrx

Lillian Skidmore joined Ambrx in 2004 and has contributed to ADC, anti-CD3 bispecific, and extended half-life protein programs.  She led the Biological Sciences team to develop in vitro methodologies, bioanalytical assays, and GMP potency assays.  Lillian currently serves as Project Leader of the aCD70 ADC program and as Associate Director of the Translational Sciences Group.

Lisa McDermott
Principal Scientist, Process and Analytical Development
MilliporeSigma

With over 25 years of experience in both organic synthesis and analytical sciences, I have had the opportunity to contribute to many projects ranging from discovery to full development, but none have been exciting as the emergence of ADCs. I joined MilliporeSigma in January of 2010 as an Analytical Project Lead responsible for ADCs.  Before, I spent seventeen years with Monsanto working on both agricultural and pharmaceutical projects followed by seven years at Pfizer focused on analytical control strategies and transfer to manufacturing.  I also have an extensive chromatography background with experience in integrated LC/MS screening systems.  I am originally from the St Louis area and live on a small farm where we raise cattle and show pigs. MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany

Day Two

Friday 22 September, 2017

07.00 | Breakfast Briefing: The Advantages of an Integrated Supply Chain

Louie Naumovski
Senior Medical Director
AbbVie

Louie Naumovski is a Senior Medical Director at AbbVie Biotherapeutics. Louie is a physician-scientist with extensive oncology drug development expertise. His interests include early clinical and pre-clinical development of novel oncology drugs and translating preclinical science into clinical proof of concept.

Maria Luz Jaramillo
Senior Research Officer & ADC Project Lead
National Research Council Canada

Maria Luz Jaramillo is a Senior Research Officer & Project Leader of the Primary Assays Teams at the National Research Council of Canada. Maria leads several projects focusing on antibody drug conjugate (ADC) development within the Human Health Therapeutics Portfolio at NRC.

Mary Jane Hinrichs
Principal Toxicologist
MedImmune

Dr. Mary Jane Masson Hinrichs is currently Principal Toxicologist in the Department of Biologics Safety Assessment at MedImmune where she is responsible for the nonclinical safety evaluation of antibody drug conjugates prior to clinical development.  In addition, she leads a translational group that conducts investigative work to evaluate the relationship between various ADC properties and safety.  Previously, Mary Jane worked at the Food and Drug Administration as a pharmacological/toxicological regulatory reviewer in the Division of Biological Oncology Products at the Center for Drug Evaluation and Research.  There, she was responsible for the review of non-clinical data used to support regulatory applications for both biologic and small molecule drugs in the field of oncology.

Campbell Bunce
Senior Vice President, Scientific Operations
Abzena

Matthew Myers
Scientist
Celgene

Matthew Myers began his scientific career at the University of Tennessee Chattanooga where he studied chemistry and biology, and was involved in an environmental biology research program in collaboration with the EPA to characterize the metabolic by-products of endogenous soil microbes found at a TN Superfund site.  He went on to pursue his PhD in biochemistry at Vanderbilt University where he studied under Dr. Daniel Liebler.  His dissertation included utilizing mass-spectrometry as a tool to investigate and quantitate changes in global protein profiles, specifically with regard to EGFR signaling perturbations.  Since joining Celgene Corporation in 2012, he has continued to use his mass-spectrometry background to target and quantitate proteins of interest while also incorporating ligand binding techniques as complimentary tools to answer scientific questions.

Michael Hay
Senior Research Investigator
Bristol-Myers Squibb

Michael Hay, Ph.D.; Senior Research Investigator II, Bristol–Myers Squibb Michael Hay completed his Ph.D. in organic chemistry in 2007 at the University of Michigan and joined the Chemical and Synthetic Development group at Bristol-Myers Squibb in 2008.  During his time at Bristol–Myers Squibb, he has contributed to and led a variety of development efforts ranging from small molecule synthetic route development and process optimization to bioconjugation process development.  As a result of this work, Michael has been an inventor on a patent application and co-authored research papers in peer reviewed journals.  Michael’s efforts are currently focused on leading bioconjugation process development efforts.

Michael Kaufman
Senior Vice President, CMC
Mersana Therapeutics

Michael Kaufman is Senior Vice President of CMC at Mersana Therapeutics.  He is responsible for all CMC functions related to ADC development, including development and manufacturing activities for antibody, payload-linker, drug substance, and drug product.   Previously, Dr. Kaufman served as Vice President, Technical Development at Biogen, Inc.  Before Biogen, Dr. Kaufman spent 10 years at Millennium/Takeda, most recently as Vice President, Pharmaceutical Sciences. Before that, he spent 15 years at Merck and Co., Inc. serving in various roles. Dr. Kaufman received a B.S. in Chemistry from the State University of New York, Stony Brook and a Ph.D. in Physical Organic Chemistry from the University of California, Berkeley.  He is the author of over 30 published articles and is named on 10 patents, and has lectured widely in the areas of preformulation, process development, and formulation.

Michelle Palmer
Director, Bioanalytical Science
ImmunoGen

Michelle Palmer is a Director of Bioanalytical Science at ImmunoGen. Michelle has executive level experience developing and implementing strategies, processes and systems for translational research. Motivated to work at the intersection of discovery and development on challenging, novel targets and pathways.

Morten Munk
Global Technology Partner
NNE

Morten Munk’s career is comprised of 30 years of experience within the global biopharmaceutical industry.   One common denominator for his work has been to ensure a holistic and broad perspective on biomanufacturing challenges from idea to established facilities. His key focus is to ensure compliant and cost-effective production through the optimal use of all relevant and available knowledge and technologies, such as single-use systems and continuous processing.   Morten joined NNE as Global Technology Partner in 2015. In 2001 he co-founded CMC Biologics, after working 14 years at Novo Nordisk.

Peter Dragovich
Principal Staff Scientist
Genentech

Peter Dragovich received a B.S. in chemistry from UC Berkeley and subsequently obtained a Ph.D. in synthetic organic chemistry from Caltech.  He has worked as a medicinal chemist in the pharmaceutical industry for more than 20 years in both large-pharma and biotech organizations.  He joined Genentech in 2010 and currently leads the company’s efforts to identify novel payloads and linkers that can be utilized for the creation of new antibody-drug conjugates.

Day One

Thursday 21 September, 2017

17.00 | Next Generation Antibody-Drug Conjugates

Phil Howard
Chief Scientific Officer
Spirogen

Dr Howard is a Founding Scientist and Chief Scientific Officer at Spirogen.  He has been conducting research into the pyrrolobenzodiazepine (PBD) family of antitumor antibiotics for twenty years in both academia and industry.  Philip has worked as a part of a multi-disciplinary team, supported by Cancer Research UK and Spirogen, on the synthesis, biological evaluation and development of the PBD dimers.  Since 2008 he has been working on the development of the PBDs as payloads for antibody-drug conjugate therapy with a number of leading companies including, Seattle Genetics, Stemcentrx, ADC Therapeutics, Genentech, Regeneron and Tanabe Research Laboratories USA Inc. Dr Howard designed the tesirine payload (SG3249) and the warhead SG3132 released by the talirine payload. His work at MedImmune is focused on the further development of their PBD-ADC platform.  At the time of writing, more than 12 PBD-ADCs, arising from Spirogen collaborations, are the subject of Phase I, Phase II, and Phase III clinical trials.

Puja Sapra
Vice President & Chief Scientific Officer
Pfizer

Puja Sapra is Vice President and Chief Scientific Officer of the Targeted Therapeutics Unit at the Oncology Research and Development, Pfizer. In this role, she leads the research group responsible for preclinical development of targeted therapeutics including antibody drug conjugate (ADCs), nanomedicines and bispecific T cell redirecting molecules. Prior to joining Pfizer, she led the Pharmacology group at Enzon Pharmaceuticals, NJ where she was responsible for the preclinical development of company’s entire portfolio including pegylated cytotoxics and locked nucleic acids (LNA)-oligonucleotides. Before Enzon, she was Senior Scientist at Immunomedics Inc. NJ, where she led preclinical development of several ADC programs and also was responsible for pharmacology assessment of company’s clinical monoclonal antibody assets. Puja has broad expertise in tumor-targeting strategies including immunotherapeutics, liposomal drug delivery system, nanoparticles, antisense oligonucleotide delivery and pegylation technologies. Puja received PhD in Pharmacology from University of Alberta on an AHFMR scholarship, in the lab of Theresa M Allen who pioneered the concept of Stealth liposomal technology that ultimately resulted in the development of Doxil®. Puja’s doctorate work focused on development of novel antibody-targeted liposomal drugs. Puja received Bachelor’s degree from the premier medical college of India, All India Institute of Medical Sciences. She was one of the two Indians selected to be awarded the prestigious British Chevening scholarship to pursue MS in Pharmacology from UK.  She is an author of >50 scientific publications, book chapters and inventor/ co-inventor on several issued patents and has been a recipient of NIH SBIR grant. She is a well-recognized expert in the targeted therapeutics field and has given numerous lectures at national and international meetings.

Day One

Thursday 21 September, 2017

08.40 | Keynote - Development of Several Classes of DNA-Damaging ADCs

Rakesh Dixit
Vice President & Global Head
Biologics Safety Assessment, MedImmune

Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since 1992. In December 1992, Rakesh joined the Department of Safety Assessment, Merck and Co., Inc, West Point, PA where he served in various management positions.  During his about 14 years with Merck, Rakesh contributed to the successful filings of many blockbuster drugs. For about a year, Rakesh was associated with Johnson and Johnson PRD, La Jolla/Alza as Senior Director of Toxicology. In Aug 2006, Rakesh joined MedImmune, Inc. (an AstraZeneca Biologics company) as Senior Director (R &D) & Global Head of Biologics Safety Assessment, Experimental Pathology, and Laboratory Animal Medicine.  In his current position as a Vice President of R &D since 2010, Rakesh is responsible for providing guidance on research and development of biological products; including nonclinical toxicology/safety support for all AstraZeneca-MedImmune biologics products, including monoclonal antibodies and vaccines.  Rakesh has published more than 60 papers in renowned international journals and has given over 100 invited lectures/presentations/workshops in national and international meetings.  Rakesh is one of the most invited speakers in the biotechnology industry.   Rakesh’s areas of expertise are mainly in the area of pharmaceuticals and biologics drug development, safety assessment of small molecule drugs, biologics, vaccines and in exploring mechanisms of toxicity and biologics pharmacological activity.  Rakesh has helped to bring several blockbuster pharmaceuticals to the market while working at Merck and Medimmune-AstraZeneca’s. Rakesh a recognized expert and key thought leader in biologics safety assessment, including ADCs and bispecifics.  Rakesh is the Editor-in-chief of Toxicology Mechanisms and Methods and Associate Editor for Toxicology Applied Pharmacology, and Journal of Toxicology and Environmental Health. Rakesh was selected by his pharmaceutical peers as the 100 Most Inspiring People in Pharmaceutical Industry by PharmaVOICE in 2015.  Rakesh also serves as an expert reviewer and in appointed committee for many programs managed by the prestigious U.S. National Academy of Sciences and US National Institutes of Health, including National Cancer Institute.

Day One

Thursday 21 September, 2017

09.10 | Minimizing Off-Target Toxicity & Improve Targeting to Tumor Associated Antigens

Richard Denk
Head of Sales Containment
SKAN

Richard Denk is working at the company SKAN AG, headquartered in Allschwil  in the position Head Sales Containment. Mr. Denk founded 8 years ago the expert Containment group of the ISPE D / A / CH. The Containment Group published the Containment Manual Mr. Denk was responsible for in September 2015. Mr. Denk has spent nearly 20 years with the subject production of highly active / highly hazardous substances and has developed the containment pyramid.

Richard Wooster
Chief Scientific Officer
Tarveda Therapeutics

Richard Wooster is President of R&D and Chief Scientific Officer at Tarveda Therapeutics. Previously he was Vice President and Discovery Performance Unit Head in Oncology at GlaxoSmithKline. During his academic career he discovered the breast cancer susceptibility gene BRCA2, and was one of the founders of the Cancer Genome Project at the Welcome Trust Sanger Institute where, among many achievements, mutations in BRAF were first discovered and he developed the COSMIC mutation database and web site.

Robert Bayer
Director
Althea

Robert Bayer is currently Director, ADC Process Development and Tech Transfer at Ajinomoto Althea. His previous experience in ADC process development includes Novartis and Genentech.  He has worked in the area of bioconjugation for more than 15 years, including developing methods for enzymatic conjugation to glycans. Robert has a Ph.D. in Biochemistry from Cornell University, and a B.S. in Chemistry from the University of Michigan.

Ron Lin
Chief Executive Officer
AbGenomics

Dr. Lin is founder and CEO of AbGenomics. To efficiently collaborate with top talents and key opinion leaders in both inflammation and cancer fields, the company established twin-headquarters in both San Francisco Bay Area and Taipei. He is the key inventor of 13 granted and 13 pending worldwide patents. Under his leadership and well established collaborative culture, the company discovered 6 promising new therapeutic candidates and has filed 5 INDs and completed 4 mid-stage clinical trials successfully. The lead compound his team discovered has demonstrated significant clinical proof of efficacy in 3 different diseases. Prior to joining AbGenomics, Dr. Lin was founding Professor and Director of Graduate Institute of Immunology, College of Medicine, National Taiwan University. He received his “Diplom” Degree in Biotechnology, Summa Cum Laude, and Doctor Degree in Immunology, Magna Cum Laude, from the University of Tübingen in Germany. He has conducted his research works in Max Planck Institute for Immunogenetics in Germany (with Dr. Jan Klein), Basel Institute for Immunology in Switzerland, and Immunobiology Division at Howard Hughes Medical Institute at Yale University (with Dr. Charles Janeway).

Russell Dushin
Associate Research Fellow
Pfizer

Russell Dushin received his Ph.D. in Organic Chemistry in 1989 from Cornell University (under John McMurry) and subsequently completed an American Cancer Society postdoctoral fellowship at Yale (under Samuel Danishefsky). In 1991, he joined American Cyanamid’s Lederle Laboratories in Pearl River, NY, as a medicinal chemist, and continued in that role following the merge with American Home Products in 1994 (forming Wyeth) as well as through the acquisition of Wyeth by Pfizer in 2009. Throughout his industrial career he has worked as a medicinal chemist in areas of antiviral and antibacterial research, cardiovascular diseases, inflammation, neuroscience, and oncology. Russell is author or co-author of over 42 peer-reviewed publications and over 31 patents and patent applications. He currently serves as an Associate Research Fellow in the Applied Synthesis Technologies group at Pfizer in Groton, CT.

Scott Dylla
Chief Scientific Officer
AbbVie-Stemcentrx

Scott is the VP of R&D and CSO of AbbVie Stemcentrx LLC, a wholly owned entity of AbbVie (ABBV)  and located in South San Francisco, CA. AbbVie Stemcentrx is pioneering the discovery and development of cancer-stem cell (CSC)-targeted ADCs, with more than 6 programs in clinical development. Prior to founding Stemcentrx in 2008, which was acquired by AbbVie in June 2016, Scott was one of the first scientists at OncoMed Pharmaceuticals, where he spearheaded the identification and characterization of solid tumor CSC, and led seminal work to identify colorectal CSC and demonstrate their resistance to chemotherapy. Scott received his BS in Biochemistry & Molecular Biology from the University of Minnesota-Duluth, a Master’s Degree in Molecular Pathobiology from the University of Alabama-Birmingham, and his doctorate in Immunology & Cancer Biology from the University of Minnesota. Scott moved to California in 2002 to postdoc at Stanford University with stem cell pioneer, Irv Weissman, and in 2005 was recognized by the British Council as one of eight outstanding young US-based researchers in the field of stem cell biology.

Day One

Thursday 21 September, 2017

18.30 | Chair’s Closing Remarks

08.00 | Chair’s Opening Remarks

Day Two

Friday 22 September, 2017

17.00 | Chair’s Closing Remarks

08.00 | Chair’s Opening Remarks

Seema Kumar
Associate Director
EMD Serono

Dr. Kumar is a Group Lead and Principal Scientist in Pharmacokinetics Pharmacodynamics and Metabolism (PDM) department at Pfizer Inc. She leads bioanalytical group that provides regulated support including assay development, validation and sample analysis for the assessment of pharmacokinetics (PK) and immunogenicity (ADA and Nab) in pre-clinical and clinical development of Pfizer’s biotherapeutics portfolio. Dr. Kumar also provides compliance oversight to Core Automation Team (CAT) engaged in automated large-molecule bioanalysis using robotic liquid handlers. Prior to joining Pfizer, Dr. Kumar held similar role as Director of CLIA certified Clinical Bioanalytical Lab at XBiotech USA Inc. Dr. Kumar holds a Ph.D. in Biophysical Chemistry from Johns Hopkins University, and has published several publications in peer-reviewed journals and contributed to book chapters, and has also presented her research in various national and international conferences and scientific meetings.

Sharon McGonigle
Principal Scientist
Eisai

Sharon McGonigle is a Principal Scientist at Eisai Inc., where she leads pre-clinical biology on discovery and early development programs in oncology.  Her experience spans target validation and mechanism of action activities in early discovery to IND-enabling studies and guidance and support of preclinical programs through clinical introduction and translational studies.  Prior to Eisai she worked at 2 start-up biotechnology companies in the Boston area in similar roles.  Her post-docs were at MUSC and Cornell University and she completed her PhD in Dublin, Ireland.

Day Two

Friday 22 September, 2017

09.10 | Chlorotoxin in Peptide Drug Conjugates: Improved Understanding of Tumor Targeting

Shawn Owen
Assistant Professor
University of Utah

Shawn C. Owen, Ph.D is an Assistant Professor in Pharmaceutics and Pharmaceutical Chemistry and Adjunct Professor of Internal Medicine at the University of Utah. He is also a member of the Huntsman Cancer Institute Experimental Therapeutics Program and the Nano-Institute of Utah. Prior to his position in Utah, he was a Postdoctoral Fellow at the University of Toronto. Current research in his lab focuses on evaluating the pharmaceutic stability of antibody-based therapeutics, creating ADCs that induce self-amplifying therapeutic cascades, and engineering antibody-split enzyme systems for diagnostic applications.

Siddharth Sukumaran
Drug Development Scientist,
Genentech

Siddharth Sukumaran is a drug development scientist at Genentech. He received his doctoral and post-doctoral training from University at Buffalo. His technical expertise is in translational pharmacokinetics and pharmacodynamics, mechanistic modeling and Quantitative Systems Pharmacology (QSP) modeling. His drug development experience spans multiple therapeutic areas including oncology, immuno-oncology, immunology and inflammatory diseases and has extensive experience with monoclonal antibodies, ADCs, fusion proteins and bispecific/multimeric antibody formats. He has been an author or co-inventor of more than 20 research articles, reviews, book chapters, and patents and has been an invited speaker to numerous conferences.

Thomas Nittoli
Director, R&D Chemistry
Regeneron Pharmaceuticals

Tom Nittoli has over 20 years of experience in the pharmaceutical industry and is currently Director of R&D Chemistry.  Dr. Nittoli joined Regeneron in 2010 to advance conjugated antibodies and proteins from discovery to development.  Since joining Regeneron, he has developed a variety of small molecules for protein conjugation, lead diverse teams of discovery ADC scientists, and lead cGMP synthesis and conjugation campaigns. Prior to Regeneron, Dr. Nittoli held positions at Pfizer, Wyeth, and CIBA-Giegy.  He holds a PhD from the department of chemistry SUNY Stony Brook in the lab of Scott Sieburth and was a post-doctoral fellow at UPenn in the labs of Amos B. Smith, III and Ralph Hirshmann.  

Thomas Pillow
Senior Scientist
Genentech

Thomas Pillow received his Ph.D from Stanford University in organic chemistry under the direction of Professor Paul Wender on the design, synthesis, and evaluation of novel drug delivery methodologies. Upon graduation he moved to Genentech where he is currently a senior scientist in the discovery chemistry department leading Genentech’s chemistry effort on antibody-drug conjugates.

Tim Lowinger
Chief Scientific Officer
Mersana

Dr. Lowinger joined Mersana in 2008, where he is responsible for all drug discovery and novel platform discovery efforts.  Prior to joining Mersana, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in the areas of oncology, asthma, urology, virology, diabetes, and Alzheimer’s disease.  Most notably, he led the discovery team and is a co-inventor of the pioneering anti-angiogenic, multi-kinase inhibitor Nexavar, approved for the treatment of kidney, liver and thyroid cancers.  Dr. Lowinger earned a B.Sc. (Hons.) in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia in Vancouver, Canada, and he was a Merck Postdoctoral Fellow at the Ohio State University in the labs of Professor Leo A. Paquette.

Kourosh Kahoussi
Principal Engineer
Pfizer

Kourosh is a chemical engineer with 15 years biotech experience working as a principal engineer in the Manufacturing Science and Technology (MSAT) group within Pfizer Global Supply (PGS).  As a member of the MSAT group Kourosh serves as a technical SME for ADC and vaccine DS and DSI processes to ensure manufacturing robustness, enhance process understanding and evaluate new processing technologies.  Previous ADC related work history includes process development for a pivotal DSI, followed by scale up and process implementation.  Other experience includes process modeling/design, technology transfer/ scale-up, production suite design/start-up and clinical manufacturing for ADC and vaccine DS and DSI processes.

Tony Cano
Senior Director, Process Development
AbbVie-Stemcentrx

Tony Cano received his B.E. in Chemical Engineering cum laude from Vanderbilt University in 1999, and his Ph.D. in Chemical Engineering from University of Houston in 2004. Following graduate school Tony joined Genentech where he was involved in the process development, technology transfer and validation of several clinical and commercial biopharmaceutical processes.  While at Genentech Tony also played a key role in the development of modern risk-based approaches for validation of biopharmaceutical processes.  Tony joined Stemcentrx in 2013 and is currently Director of Process Sciences where he oversees cell culture, purification, conjugation, analytical and formulation development groups.

Travis Young
Principal Investigator
California Institute for Biomedical Research

My research is focused on using protein engineering to study how the biophysical nature of antibody-based therapeutics affect the physiological response of the cells they engage.  I am a member of the founding principal investigators of the California Institute for Biomedical Research (Calibr) where I currently have a group in immuno-oncology.  Our research is focused on bispecific antibodies, antibody drug conjugates, and CAR-T cells - combining novel technologies to produce therapeutics for important unmet medical needs.

Vikram Sisodiya
Associate Director
AbbVie-Stemcentrx

Vikram Sisodiya is an Associate Director in Process Sciences at AbbVie Stemcentrx, leading ADC development.  He joined Stemcentrx in 2012 and has since led the conjugation process development for several programs ranging from early research/POC evaluations to Phase I/II clinical manufacturing, including Rova-T.  Prior to joining Stemcentrx in 2012, Vikram was a process development engineer at Genentech, developing early stage purification and conjugation processes for several Phase I programs.  

Wendy Saffell-Clemmer
Director, Research
BioPharma Solutions

Wendy Saffell-Clemmer is the Director of the Baxter Biopharma Solutions (BPS) R&D team.  The BPS R&D team offers contract development services for small volume liquid (vial and syringe) and lyophilized products which are manufactured for external clients both at Baxter’s Bloomington, IN and Halle, Germany facilities.  Services include formulation development, lyophilization cycle development, container compatibility and analytical development for small molecules, peptides, proteins, MaBs, ADCs and vaccines.  Additionally the team performs analytical method validation, transfer and lifecycle maintenance for the QC laboratory as well as cleaning validation method development and validation.   Prior to joining Baxter in 2002, Ms. Saffell-Clemmer worked in Bioprocess Research and Development at Eli Lilly in Indianapolis.  She volunteers as the Vice-Chair of the USP Expert Committee for Biological Analysis-General Chapters, the USP Expert Panel for Protein Measurement, and the USP Expert Panel for Validation of Commercial Test Kits.

Xiao Hong
Quality Assessment Lead, New Drug Quality Assessment Division
FDA

Dr. Xiao Hong Chen has been a Quality Assessment Lead in the Office of New Drug Quality Assessment, Division 1, Branch 2 since 2015. She has been working at FDA as a CMC reviewer, senior reviewer and master reviewer for small molecule drug for more than 10 years. Together with the reviewers for biologics, she reviewed all three ADCs approved by the FDA since 2000. Dr. Chen received her Ph.D. in molecular and cellular biology and biochemistry from University of Massachusetts at Amherst. She did her post-doctoral research at National Cancer Institute.  

Kwasi Antwi
Application Scientist for Mass Spectrometric Immunoassay (MSIA)
Thermo Fisher Scientific

Kwasi Antwi was born in Ghana and received his PhD in 2006 from the Department of Chemistry in the University of Massachusetts, Amherst. In 2009, he completed his postdoctoral fellowship in Professor Douglas Lake’s Lab at the Arizona State University. He was then promoted to a Research Faculty position in the School of Life Sciences at Arizona State University, where he focused his research on studying biomarkers for cancers and infectious diseases. In 2013, he joined Thermo Fisher Scientific as the Application Scientist for the MSIA (Mass Spectrometric Immunoassay) group. At his current position at Thermo Fisher Scientific, Dr. Antwi has developed several immunoassay and LC-MS methods to study biomolecules, including monoclonal antibodies, antibody drug conjugates, fusion proteins, insulin, etc. His work has been published in applications notes, which are being utilized by the Biopharma industry to study biomolecules.

Jeff Raizer
Executive Medical Director, Clinical Science
Celldex